Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.96 |
| ▸ | RAB9A | P51151 | 9/20 | 0.96 |
| ▸ | PKM | P14618 | 6/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.96 |
| ▸ | TP53 | P04637 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.96 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.96 |
| ▸ | RELA | Q04206 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357942 | 1.00 | NPC1 (0.96) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL21500665 | 0.89 | NPC1 (0.77) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL21500673 | 0.89 | NPC1 (0.77) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL24038344 | 0.87 | NPC1 (0.74) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL21500721 | 0.86 | NPC1 (0.72) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL22080077 | 0.85 | NPC1 (0.72) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL16217098 | 0.85 | SLC2A1 (0.97) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL24038343 | 0.85 | NPC1 (0.70) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL27223409 | 0.84 | NPC1 (0.74) | NPC1RAB9APKMTAAR1SMN1; SMN2 | |
| SCHEMBL21497081 | 0.83 | NPC1 (0.68) | NPC1RAB9APKMTAAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739306-A2 | POLO-LIKE KINASE 1 INHIBITORS | Cervero Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | US | disclosed |
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| WO-2008056149-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
| EP-1366027-B1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | UNIV MCGILL (CA) | 2006-09-20 | — | — | EP | disclosed |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | QIU, QIYU | 2004-05-06 | — | — | US | disclosed |
| EP-1366027-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | McGILL UNIVERSITY (CA) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068396-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | MCGILL UNIVERSITY (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | MBNL1, HNRNPUL1, HNRNPUL2 | NPC1 3300/4885RAB9A 2407/4885PKM 3030/4885 |
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | ADRB1, ADRB2, ADRA2B | NPC1 3319/4885RAB9A 1205/4885PKM 2978/4885 |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | EGFR, PCNA, ERCC2 | NPC1 4825/4885RAB9A 3994/4885PKM 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.